Introduction
Targeted cancer therapies have been designed to interact with particular proteins associated with tumor development or progression. Many of these agents are tyrosine kinases inhibitors (TKIs), targeting enzymes whose disregulated expression and activity are associated with various cancers. 1 The pioneer small-molecule TKI imatinib has revolutionized the treatment and prognosis of chronic myeloid leukemia (CML). Imatinib inhibits the tyrosine kinase Bcr-Abl, 2 a fusion oncoprotein resulting from the translocation t(9;22)(q34;q11), 3 which is associated with the characteristic Philadelphia chromosome, 2 a hallmark of chronic myeloid leukemia and of some acute lymphoblastic leukemias. 4 However, some patients, especially those in the advanced phase of the disease, develop resistance to imatinib therapy, because of various mechanisms such as BCR-ABL gene amplification, 5 low imatinib absorption, or more frequently point mutations into the oncoprotein sequence. 6 Several new inhibitors have been developed with increased potency and a broader range of activity against imatinib-resistant mutants. In vitro studies have shown that nilotinib, an imatinib derivative, and dasatinib, structurally unrelated to imatinib, are, respectively, 20-and 300-fold more potent than imatinib against unmutated Abl 7 and are active against many imatinib-resistant Bcr-Abl mutants. 7 TKIs are extensively metabolized by cytochrome P450 enzymes (CYP), whose activities are characterized by a large degree of interindividual variability. 8 Some TKIs are also substrates or inhibitors of the drug transporters P-glycoprotein (Pgp; coded by ABCB1) Breast Cancer Resistance Protein (BCRP; ABCG2) and the organic cation transporter 1 (hOCT1; SLC22A1). [9] [10] [11] [12] [13] A standard regimen can therefore produce very different circulating and cell concentration profiles from one patient to another, thus favoring the selection of resistant cellular clones by subtherapeutic drug exposure or the occurrence of toxicity in case of overexposure. 14, 15 Identifying the best active and safe dosing schedule for individual patients to maximize therapeutic benefit has become a scientific and clinical challenge. Combination therapies have been investigated in various conditions, which certainly add a level of treatment complexity, because overlapping toxicities and pharmacokinetic interactions have to be taken into consideration. 16, 17 We review here systematically and present under an easyconsulting form (Table 1 ) the information available on pharmacologic interactions between imatinib, dasatinib, and nilotinib and drugs concomitantly prescribed to patients receiving TKIs. The drugs were selected on the basis of the information extracted from our database, used within the framework of Therapeutic Drug Monitoring of TKIs. 15 Moreover, classical inhibitors or inducers of cytochromes P450 or drug transporters were also included in this review. We do not intend here to replace individualized medical evaluation, and the data presented here should be used in addition to thorough clinical judgment. Indeed, it may be that our searches still missed some interactions, and actually most interactions do not represent true contraindications but rather call for appropriate dosage adjustments and treatment monitoring measures.
Review of the literature
In addition to official monographs of the drugs, 9 literature from Medline and Evidence-Based Medicine Reviews was systematically searched, using the following MeSH terms: "Drug interactions," "Cytochrome P-450 Enzyme System," "P-Glycoprotein," "ABCG2 protein," "organic cation transporter 1," "Protein binding," and the respective TKI and concomitant drugs names. In addition, 2 drug information databases (UpToDate online 18 and Cancer Care Ontario 19 ) were screened, and abstracts of international and national conferences, review articles, and references given in identified articles were also scanned. [20] [21] [22] All relevant cited literature on pharmacokinetic or pharmacodynamic interactions was considered for inclusion in Table 1 .
Drug interactions were either clinically documented or derived from mechanistic considerations on proven or putative metabolic pathways, protein binding, and transmembrane transport. When data on a particular combination were unavailable, potential interactions were extrapolated from the reported disposition mechanisms of the agents and of similar substrates.
Interaction with imatinib
Imatinib is metabolized mainly by CYP isoenzyme 3A4, whereas CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A5 are reported to play a minor role in its metabolism. 11 This TKI has also been shown to be a substrate of hOCT1, Pgp, and BCRP. 9, [23] [24] [25] However, a controversial report 26 suggests that imatinib is an inhibitor rather than a substrate of BCRP, thus leaving uncertainty about the role of this pathway. The metabolites of imatinib are eliminated predominantly through biliary excretion. One metabolite, an N-demethylated piperizine derivative (CGP 74588) shows pharmacologic activity comparable to the parent drug, but the • 2 dasatinib absorption 9 ( 2 dasatinib solubility)
• Inhibition of Pgp by pantoprazole:
1 dasatinib exposure 9,18,64 -
H2-antagonists

Cimetidine
• Inhibition of CYP 3A4 and Pgp by cimetidine:
1 imatinib exposure 18, 65 • Inhibition of hOCT1 by cimetidine:
2 imatinib intracellular exposure 18, 64, 65 • 2 dasatinib absorption 9 ( 2 dasatinib solubility)
1 dasatinib exposure 18, 65 • Inhibition of CYP 3A4 by cimetidine:
1 nilotinib exposure 18, 65 Ranitidine • Inhibition of Pgp by ranitidine:
1 imatinib exposure 18, 65 • Inhibition of hOCT1 by ranitidine:
2 imatinib intracellular exposure 9, 18, 64, 65 • 2 dasatinib absorption 9 ( 2 dasatinib solubility)
• Inhibition of Pgp by ranitidine: 1 glibenclamide exposure 9, 18, 19 • Inhibition of Pgp by glibenclamide:
1 imatinib exposure 9, 18, 64 • Inhibition of CYP 3A4 by dasatinib:
1 glibenclamide exposure 9, 18, 19 • Inhibition of Pgp by glibenclamide:
1 dasatinib exposure 9, 18, 64 • Inhibition of CYP 3A4 and 2C9 by nilotinib:
1 glibenclamide exposure 9, 18, 19 Acarbose ---
Rosiglitazone
• Inhibition of CYP 2C9 by imatinib:
1 rosiglitazone exposure 9, 18, 19 -• Inhibition of CYP 2C9 by nilotinib:
1 rosiglitazone exposure 9, 18, 19 Pioglitazone • Inhibition of CYP 3A4 and 2C9 by imatinib:
1 pioglitazone exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 pioglitazone exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2C9 by nilotinib:
1 pioglitazone exposure 9, 18, 19 Nateglinide • Inhibition of CYP 3A4 and 2C9 by imatinib:
1 nateglinide exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 nateglinide exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2C9 by nilotinib:
1 nateglinide exposure 9, 18, 19 Repaglinide • Inhibition of CYP 3A4 by imatinib:
1 repaglinide exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2C8 by dasatinib:
1 repaglinide exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2C8 by nilotinib:
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For personal use only. by guest on May 10, 2013. bloodjournal.hematologylibrary.org From systemic exposure represents ϳ 15% of that for imatinib. 13 The fecal-to-urinary excretion ratio is ϳ 5:1. Moreover, imatinib can competitively inhibit the metabolism of drugs that are CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates. 13 Imatinib is ϳ 95% bound to human plasma proteins, mainly albumin and ␣1-acid glycoprotein. 11, [27] [28] [29] Interactions should therefore be considered when administering inhibitors of the CYP3A family in combination with imatinib. Strong inhibition, such as achieved with ketoconazole, caused a 40% increase of imatinib exposure in healthy volunteers. 30 Interactions are likely to occur with other inhibitors of CYP3A4, such as levothyroxine 31, 32 voriconazole, 33 or amiodarone, 34 leading to an increase in plasma concentrations of imatinib. Nevertheless, a study suggests that inhibition of CYP3A4 by the potent irreversible inhibitor ritonavir does not result in increased steady-state plasma concentrations of imatinib, possibly because of the induction of compensatory metabolism or transport mechanisms by ritonavir. 35 Concomitant administration of imatinib with inhibitors of both CYP3A4 and Pgp increase not only plasma but also intracellular imatinib concentrations. Dual CYP3A4 and Pgp inhibitors such as verapamil, 9 erythromycin, 36 clarithromycin, 36 ciclosporin, 37, 38 ketoconazole, 30 fluconazole, 9, 18 and itraconazole 9, 18 increase intracellular concentrations of imatinib by inhibiting both its metabolism and its efflux by Pgp and might therefore increase its cellular toxicity.
Moreover, inhibition of Pgp by proton pump inhibitors such as pantoprazole was shown to increase brain penetration of imatinib. 40 Conversely, another study reported that concomitant administration of a Mg 2ϩ -Al 3ϩ -based antacid is not associated with meaningful alterations in imatinib absorption. 41 Concomitant administration of CYP3A4 inducers such as rifampicin or certain antiepileptics may lead to a reduction of as much as 74% in imatinib exposure. 12, 13, 42 Moreover, the pharmacokinetic profile of imatinib was significantly altered by St John's wort, with reductions of 30% in the median area under the concentration-time curve (AUC). 43, 44 Concomitant use of enzyme inducers, including St John's wort, may thus necessitate an increase in imatinib dosages to maintain clinical effectiveness. 43, 44 Interactions with quinidine, ranitidine, or midazolam, known inhibitors of hOCT1, may paradoxically increase the circulating concentrations of imatinib but decrease the intracellular exposure of target cancer cells, known to express this carrier. 9, 25 With regard to all these mechanisms, it is worth recalling that plasma concentrations of imatinib appear correlated with efficacy and toxicity. 29, [45] [46] [47] A change in imatinib exposure because of a drug interaction might therefore definitely influence its therapeutic efficacy.
TKIs can also inhibit drug transporters and enzymes, leading to changes in the exposure of coadministered drugs. Imatinib enhances the intestinal absorption of ciclosporin, a CYP3A4 and Pgp substrate, and may increase the pharmacologic effects and possibly toxicity of ciclosporin. 37, 38 Moreover, the clearance of simvastatin (a CYP3A4 substrate) was reduced by 70% when associated with imatinib. 13 Administration of imatinib together with metoprolol, a CYP2D6 substrate, resulted in an increase in metoprolol exposure by 23%. 13 Data concerning interactions involving protein binding are poorly documented for imatinib. A study showed that St John's wort does not alter the protein binding of imatinib over a wide range of concentrations in vivo. 43, 44 Interactions of potential clinical relevance can occur with calcium channel blockers such as verapamil and diltiazem, substrates of CYP3A4, which circulating levels are increased 2 clopidogrel bioactivation 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 clopidogrel exposure 9, 18, 19 2 clopidogrel bioactivation 9, 18, 19 • Thrombocytopenic effect of dasatinib:
1 risk of bleeding 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 clopidogrel exposure 9, 18, 19 2 clopidogrel bioactivation 9, 18, 19 Anticoagulants*
Acenocoumarol
• Thrombocytopenic effect of dasatinib:
1 risk of bleeding 9, 18, 19 • Inhibition of CYP 2C9 by nilotinib: • Thrombocytopenic effect of dasatinib:
1 risk of bleeding 9, 18, 19 • Inhibition of CYP 2C9 by nilotinib: 1 imatinib exposure 66 • Thrombocytopenic effect of dasatinib:
1 risk of bleeding 9, 18, 19 • Inhibition of Pgp by heparin: • Inhibition of CYP 3A4 by dasatinib: 1 diltiazem exposure 9, 18 • Inhibition of CYP 3A4 and Pgp by diltiazem: 1 dasatinib exposure 9,10,52,67,68
• Inhibition of CYP 3A4 by nilotinib: 1 diltiazem exposure 9, 18 • Inhibition of CYP 3A4 by diltiazem: 1 nilotinib exposure 9, 18, 19 Nifedipine
• Inhibition of CYP 3A4 by imatinib: 1 nifedipine exposure 9, 18, 74 • Inhibition of CYP 3A4 by dasatinib: 1 nifedipine exposure 9, 18, 74 • Inhibition of CYP3A4 by nilotinib: 1 nifedipine exposure 9, 18, 74 Amlodipine
• Inhibition of CYP 3A4 by imatinib: 1 amlodipine exposure 9,18,19
• Inhibition of CYP 3A4 by dasatinib: 1 amlodipine exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib: 1 amlodipine exposure 9, 18, 19 NO precursors
• Inhibition of CYP 3A4 by imatinib: 1 ISMN exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib: 1 ISMN exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib: 1 ISMN exposure 9, 18, 19 Isosorbid dinitrate (ISDN) • Inhibition of CYP 3A4 by imatinib: 1 ISDN exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib: 1 ISDN exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib: 1 ISDN exposure 9, 18, 19 Nitroglycerine ---
HMG-CoA reductase inhibitors
Simvastatin • Inhibition of Pgp by metoprolol: 1 dasatinib exposure 9,10,52,67
• Inhibition of CYP 2D6 by nilotinib: 1 metoprolol exposure 9, 18, 19 Bisoprolol • Inhibition of CYP 2D6 by imatinib: 1 bisoprolol exposure 18 • Inhibition of CYP 3A4 by dasatinib: 1 bisoprolol exposure 9, 18 • Inhibition of CYP 2D6 by nilotinib: 1 bisoprolol exposure 9, 18, 19 Carvedilol • Inhibition of CYP 2C9 and 2D6 by imatinib: 1 carvedilol exposure 18 • Inhibition of Pgp by carvedilol: 1 imatinib exposure 64, 71, 77 • Inhibition of Pgp by carvedilol: 1 dasatinib exposure 9,10,52,67,68,77
• Inhibition of CYP 2C9 and 2D6 by nilotinib: 1 carvedilol exposure 9, 18, 19 Atenolol • Absence of interaction 9 --
ACE inhibitors
Captopril
• Inhibition of CYP 2D6 by imatinib: 1 captopril exposure 18 • Inhibition of Pgp by captopril: 1 imatinib exposure 9, 18, 23, 64, 70, 72 • Inhibition of Pgp by captopril: 1 dasatinib exposure 9,10,52,67
• Inhibition of CYP 2D6 by nilotinib: 1 captopril exposure 9, 18, 19 Enalapril For personal use only. by guest on May 10, 2013. bloodjournal.hematologylibrary.org From when associated with imatinib. 18, 19 Interactions with simvastatin, amiodarone, and quinidine, involving the same P450 isoenzyme, may also be of clinical relevance. 9, 18, 19, 48 In patients taking imatinib, such drugs should be either tapered or avoided and replaced by safer alternatives (eg, pravastatin or sotalol).
Imatinib is also known to inhibit the O-glucuronidation of acetaminophen, possibly inducing hepatotoxicity and liver failure. 9 The use of acetaminophen should be limited in patients taking imatinib. A limit has been suggested of 1300 mg acetaminophen per day. 49 Liver function tests might be useful to monitor during prolonged treatment. 50 Acenocoumarol and phenprocoumon, substrates of CYP2C9, show also increased concentrations; however, this interaction can be compensated by the monitoring of prothrombin time or international normalized ratio. 9, 18, 51 Finally, physicians should be aware that patients with hypothyroid conditions who receive imatinib need increased levothyroxine doses. 31, 32 The suspected mechanism responsible for this phenomenon is an induction of non-deiodination clearance. 31, 32 The fraction of levothyroxine that is deiodinated into biologically active triiodothyronine is mainly subject to conjugation with glucuronates and sulfates. 31, 32 Although the liver primarily mediates glucuronidation and sulfation, these conjugations occur in extrahepatic sites such as the kidney and intestine as well. 31, 32 Therefore, induction of uridine diphosphate-glucuronyl transferases (UGTs) seems to be involved. 31, 32 A 2-fold increase in levothyroxine substitution therapy at initiation of imatinib treatment is recommended, along with close monitoring of thyroid function. 31, 32 
Interaction with dasatinib
Dasatinib is metabolized in an active derivative and other inactive metabolites by the CYP3A4 isoenzyme and was also reported to be a substrate of BCRP and Pgp. 9, 18, 52 The active metabolite appears to play a negligible role in therapeutic activity. Dasatinib has an inhibitory activity against CYP2C8 and CYP3A4. Plasma protein binding is ϳ 96% for dasatinib, mainly to albumin. 53 • Inhibition of CYP 3A4 by dasatinib: 1 losartan exposure 9, 18 • Inhibition of Pgp by losartan: 1 dasatinib exposure 9,10,52,67
• Inhibition of CYP 2C9 and 3A4 by nilotinib: 1 losartan exposure and 2 losartan bioactivation 9, 18, 19 Candesartan ---
Cardiac glycosides
Digoxin
• 2 digoxin absorption 9, 18, 19 (unknown mechanism)
• 1 QT interval 19 • Induction of CYP 3A4 by dexamethasone:
2 dasatinib exposure 19 • Induction of CYP 3A4 by dexamethasone:
2 nilotinib exposure 9, 18, 19 Betamethasone ---
Thyroid therapy
Levothyroxine
• Induction of UGTs by imatinib:
• Inhibition of CYP 3A4 by levothyroxine:
1 imatinib exposure 31, 32 • Inhibition of CYP 3A4 by levothyroxine:
1 dasatinib exposure 9, 19 • Inhibition of CYP 3A4 by levothyroxine:
1 nilotinib exposure 9, 19 Carbimazole ---
Antineoplastic agents
Cyclophosphamide
• Inhibition of CYP 2D6 and 3A4 by imatinib:
1 cyclophosphamide exposure 2 cyclophosphamide bioactivation 9, 19 • Inhibition of CYP 3A4 by dasatinib:
1 cyclophosphamide exposure 2 cyclophosphamide bioactivation 9, 19 • Induction of CYP 2B6 by nilotinib: • Inhibition of CYP 3A4 by dasatinib:
1 etravirine exposure 9, 18, 19, 81 • Induction of CYP 3A4 by etravirine:
2 dasatinib exposure 9, 18, 19, 81 • Inhibition of CYP 2C9 and 3A4 by nilotinib:
2 nilotinib exposure 9, 18, 19, 81 Antimalarial drugs
Quinine
• Inhibition of CYP 3A4 by imatinib:
1 quinine exposure 9, 18, 19 • Inhibition of CYP 2D6 and Pgp by quinine:
1 imatinib exposure 9, 18, 19 • Inhibition of hOCT1 by quinine:
2 imatinib intracellular exposure 9, 18, 64 • Inhibition of CYP 3A4 by dasatinib:
1 quinine exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 quinine exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect)
monitor ECG
• Inhibition of CYP 3A4 by nilotinib:
Chloroquine
• Inhibition of Pgp by chloroquine:
1 imatinib exposure 9, 18, 19 • Inhibition of hOCT1 by chloroquine:
2 imatinib intracellular exposure 9, 18, 64 • Inhibition of Pgp by chloroquine:
1 dasatinib exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect)
3 monitor ECG
• 1 QT interval 18, 19 (additive effect)
monitor ECG
Mefloquine
• Inhibition of CYP 3A4 and Pgp by imatinib:
1 mefloquine exposure 9, 18, 19 • Inhibition of Pgp by mefloquine:
1 imatinib exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
monitor ECG
• Inhibition of CYP 3A4 and Ppg by nilotinib:
1 mefloquine exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect) 
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In healthy subjects receiving ketoconazole, systemic exposure (AUC) to dasatinib was increased by 5-fold. 39 Interactions may then occur between dasatinib and other inhibitors of CYP3A4, such as levothyroxine 31, 32 and voriconazole, 33 leading to a marked increase in plasma concentrations of this TKI. Drugs that inhibit both BCRP and CYP3A4, such as verapamil, 55 may lead to even larger increase in dasatinib exposure.
Inhibitors of both CYP3A4 and Pgp will increase not only plasma but also intracellular concentrations of dasatinib; this is expected for verapamil, 9 erythromycin, 9,18 clarithromycin, 9,18 ciclosporin, 38 ketoconazole, 39 fluconazole, 9, 18 and itraconazole. 9, 18 Concomitant administration of the CYP3A4 inducer rifampicin leads to a reduction of 80% in dasatinib exposure. 12,13,42 St John's wort, a CYP3A4 inducer, may also decrease dasatinib plasma concentrations and should be discouraged in patients receiving dasatinib. 56 Antiepileptics (phenobarbital, phenytoin, carbamazepine) are expected to decrease dasatinib concentrations as well.
Moreover, the solubility of dasatinib appears to be pH dependent. Dasatinib exposure is reduced by 61% when famotidine is administered before dasatinib dosing. 57 As a result, concomitant administration of agents that provide prolonged gastric acid suppression, such as H2 antagonists and proton pump inhibitors, is not recommended. 42 In contrast, dasatinib exposure is unchanged when Mg 2ϩ -Al 3ϩ -based antacids are administered Ն 2 hours before dasatinib; but coadministration reduced dasatinib exposure by 55%-58%. 57 Dasatinib can also slightly inhibit drug transporters and enzymes, leading to changes in the exposure of coadministered drugs. 9, 18 The coingestion of dasatinib with simvastatin resulted in a 20% increased exposure to simvastatin. 13 Concurrent use with calcium channel blockers such as verapamil and diltiazem, substrates of CYP3A4, should be avoided. 18, 51 Studies about interactions involving protein binding were unavailable for dasatinib.
In clinical trials, dasatinib treatment has been associated with prolongation of the QTc interval on electrocardiograms, and sudden cardiac deaths have occurred, which are probably related to ventricular repolarization abnormalities. 58, 59 Association of QT-prolonging drugs such as digoxin, quinolones, methadone, or several psychotropic medications, may increase the risk of such events by additive effect. 9, 19 Regular electrocardiographic controls (ECG) are strongly recommended in such situations. 58, 59 Interactions with nilotinib Nilotinib undergoes metabolism by CYP3A4. It is also a substrate of the efflux transporter BCRP. 9, 23 Nilotinib is known to inhibit CYP2C8, CYP2C9, CYP2D6, CYP3A4, UGT1A1, and Pgp. In vitro studies suggest that nilotinib also induces CYP2B6 enzymes. 19 Note that UGT1A1 inhibition has been associated with an increase in bilirubin levels (especially in 1 ciclosporin exposure 37, 38 • Inhibition of Pgp and CYP 3A4 by ciclosporin:
1 imatinib exposure 37, 38 • Inhibition of CYP 3A4 by dasatinib:
1 ciclosporin exposure 9, 18, 19, 82 • Inhibition of CYP3A4 and Pgp by ciclosporin:
1 dasatinib exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 and Pgp by nilotinib:
1 ciclosporin exposure 9, 18, 19, 82 • Inhibition of CYP3A4 by ciclosporin:
1 nilotinib exposure 9, 18, 19, 82 Tacrolimus • Inhibition of CYP 3A4 by imatinib:
1 tacrolimus exposure 9, 18, 19, 82 • Inhibition of Pgp by tacrolimus:
1 imatinib exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 by dasatinib:
1 tacrolimus exposure 9, 18, 19, 82 Sirolimus • Inhibition of CYP 3A4 and Pgp by imatinib:
1 sirolimus exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 by dasatinib:
1 sirolimus exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 and Pgp by nilotinib:
1 sirolimus exposure 9, 18, 19, 82 Everolimus • Inhibition of CYP 3A4 and Pgp by imatinib:
1 everolimus exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 by dasatinib:
1 everolimus exposure 9, 18, 19, 82 • Inhibition of CYP 3A4 and Pgp by nilotinib:
1 everolimus exposure 9, 18, 19, 82 Mycophenolate mofetil --- 1 ibuprofen exposure 9, 18, 83, 84 • Inhibition of CYP 2C8 by dasatinib:
1 ibuprofen exposure 9, 18, 83, 84 • Inhibition of CYP 2C8 and 2C9 by nilotinib:
1 ibuprofen exposure 9, 18, 83, 84 Mefenacid • Inhibition of CYP 2C9 by imatinib:
1 mefenacid exposure 9, 18, 19 • Inhibition of CYP 2C8 by dasatinib:
1 mefenacid exposure 9, 18, 19 • Inhibition of CYP 2C8 and 2C9 by nilotinib:
1 mefenacid exposure 9, 18, 19 Metamizole • Induction of CYP 3A4 by metamizole:
2 imatinib exposure 9,18,85
• Induction of CYP 3A4 by metamizole:
2 dasatinib exposure 9,18,85
2 nilotinib exposure 9,18,85
Diclofenac
1 diclofenac exposure 9, 18, 86 • Inhibition of Pgp by diclofenac:
1 imatinib exposure 9, 18, 86 • Inhibition of CYP 2C8 by dasatinib:
1 dasatinib exposure 9, 18, 86 • Inhibition of CYP 2C8 and 2C9 by nilotinib:
1 diclofenac exposure 9, 18, 86 Antigout preparations 1 fluoxetine exposure 9, 18, 19, 87, 88 • 1 QT interval 9, 18, 19, 87, 88 (additive effect)
monitor ECG
• 1 QT interval 9, 18, 19, 87, 88 1 citalopram exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 citalopram exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 citalopram exposure 9, 18, 19 Sertraline • Inhibition of CYP 3A4 and 2D6 by imatinib:
1 sertraline exposure 9, 18, 19, 87 • Inhibition of CYP 3A4 by dasatinib:
1 sertraline exposure 9, 18, 19, 87 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 sertraline exposure 9,18,19,87
SSNRI
Venlafaxine
• Inhibition of CYP 3A4 and 2D6 by imatinib:
1 venlafaxine exposure 9, 18, 19, 87 • Inhibition of CYP 3A4 by dasatinib:
1 venlafaxine exposure 9, 18, 19, 87 • 1 QT interval 18, 19 (additive effect)
• Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 venlafaxine exposure 9, 18, 19, 87 • 1 QT interval 18, 19 (additive effect) 1 duloxetine exposure 9, 18, 19 Tetracyclic agent
Mirtazapine
1 mirtazapine exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 mirtazapine exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 mirtazapine exposure 9, 18, 19 Tricyclic agents
Trimipramine
• Inhibition of CYP 2D6 by imatinib:
1 trimipramine exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect)
3 monitor ECG • Inhibition of CYP 2D6 by nilotinib:
1 trimipramine exposure 9, 18, 19 Amitriptyline • Inhibition of CYP 3A4 and 2D6 by imatinib:
1 amitriptyline exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 amitriptyline exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect)
monitor ECG
1 amitriptyline exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect) 
Z-drugs
Zolpidem
1 zolpidem exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 zolpidem exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 zolpidem exposure 9, 18, 19 Zaleplon • Inhibition of CYP 3A4 by imatinib:
1 zaleplon exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 zaleplon exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 zaleplon exposure 9, 18, 19 Zopiclon • Inhibition of CYP 3A4 by imatinib:
1 zopiclon exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 zopiclon exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 zopiclon exposure 9, 18, 19 Benzodiazepines Alprazolam • Inhibition of CYP 3A4 by imatinib:
1 alprazolam exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 alprazolam exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 alprazolam exposure 9, 18, 19 Bromazepam • Inhibition of CYP 3A4 by imatinib:
1 bromazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 bromazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 bromazepam exposure 9, 18, 19 Clonazepam • Inhibition of CYP 3A4 by imatinib:
1 clonazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 clonazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 clonazepam exposure 9, 18, 19 Oxazepam ---
1 diazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 diazepam exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 diazepam exposure 9, 18, 19 Midazolam • Inhibition of CYP 3A4 by imatinib:
1 midazolam exposure 9, 18, 19 • Inhibition of Pgp by midazolam:
1 imatinib exposure 9, 18, 19 • Inhibition of hOCT1 by midazolam:
1 dasatinib exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 midazolam exposure 9, 18, 19 Barbiturates Phenobarbital • Inhibition of CYP 2C9 and 2C19 by imatinib:
1 phenobarbital exposure 9, 18, 19 • Induction of CYP 3A4 by phenobarbital:
2 imatinib exposure 9, 18, 19 • Induction of CYP 3A4 by phenobarbital:
2 dasatinib exposure 9, 18, 19 • Inhibition of CYP 2C9 by nilotinib:
2 nilotinib exposure 9, 18, 19 Antipsychotic agents
Haloperidol
1 haloperidol exposure 9,18,19
• Inhibition of CYP 3A4 by dasatinib:
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For personal use only. by guest on May 10, 2013. bloodjournal.hematologylibrary.org From patients homozygous for the UGT1A1*28 reduced-function variant). 60 The determination of UGT1A1*28 is therefore approved by the Food and Drug Administration as a valid pharmacogenetic test for patients treated by nilotinib. 61 This TKI is ϳ 98% bound to albumin and ␣1-acid glycoprotein. 54 Nilotinib exposure is expected to increase under CYP3A4 inhibitors. For example, AUC of nilotinib was increased by a 3-fold factor in healthy subjects receiving ketoconazole. 12 Moreover, a study showed that concurrent intake of 240 mL of grapefruit juice increased by 60% nilotinib AUC. Concomitant administration of nilotinib with grapefruit juice is therefore not recommended. 62 Conversely, concomitant administration of CYP3A4 inducers such as rifampicin leads to a reduction by a 4.8 factor in nilotinib exposure. 12, 13, 42 Literature about interactions involving protein binding were lacking for nilotinib.
The same potential clinically significant interactions with imatinib and dasatinib can occur with nilotinib. For example, acenocoumarol and phenprocoumon, substrates of CYP2C9, show increased concentrations, imposing careful monitoring of prothrombin time or international normalized ratio. 9 Moreover, as with dasatinib, nilotinib has been associated with prolongation of the QTc interval, and cases of sudden cardiac death have 1 clozapine exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 clozapine exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 clozapine exposure 9, 18, 19 Olanzapine ---
Risperidone
1 risperidone exposure 9, 18, 19 • 1 QT interval 18, 19 (additive effect)
Antiseizure drugs
Phenytoin
• Induction of CYP 3A4 by phenytoin:
2 imatinib exposure 9, 18, 19 • Induction of CYP 3A4 by phenytoin:
2 dasatinib exposure 9, 18, 19 • Induction of CYP 3A4 by phenytoin:
2 nilotinib exposure 9, 18, 19 Valproic acid • Inhibition of CYP 2C9 and 2C19 by imatinib:
1 valproic acid exposure
• Inhibition of CYP 3A4 by valproic acid:
1 imatinib exposure 9, 18, 19 • Inhibition of CYP 3A4 by valproic acid:
1 dasatinib exposure 9, 18, 19 • Inhibition of CYP 2C9 by nilotinib:
•Inhibition of CYP 3A4 by valproic acid:
1 nilotinib exposure 9, 18, 19 Carbamazepine • Induction of CYP 3A4 and Pgp by carbamazepine:
2 imatinib exposure 9, 18, 19 • Induction of CYP 3A4 and Pgp by carbamazepine:
2 dasatinib exposure 9, 18, 19 • Induction of CYP 3A4 by carbamazepine:
2 nilotinib exposure 9, 18, 19 Lamotrigine ---
• Induction of CYP 3A4 by topiramate:
2 imatinib exposure 9, 18, 19 • Induction of CYP 3A4 by topiramate:
2 dasatinib exposure 9, 18, 19 • Induction of CYP 3A4 by topiramate:
2 nilotinib exposure 9, 18, 19 Levetiracetam --- • Inhibition of CYP 3A4 by dasatinib:
Antimaniac drug
1 tramadol exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 tramadol exposure 9, 18, 19 2 tramadol bioactivation 9, 18, 19 Methadone • Inhibition of CYP 3A4 by imatinib:
1 methadone exposure 9, 18, 19 • Inhibition of Pgp by methadone:
1 imatinib exposure 9, 18, 19 • 1QT interval 18, 19 (additive effect)
monitor ECG
1 methadone exposure 9, 18, 19 • Induction of CYP 2B6 by nilotinib:
2 methadone exposure 19 • 1 QT interval 18, 19 (additive effect) • Inhibition of CYP 3A4 by dasatinib:
1 oxycodone exposure 9, 18, 19 • Inhibition of CYP 3A4 and 2D6 by nilotinib:
1 oxycodone exposure 2 oxycodone bioactivation 9, 18, 19 Buprenorphine • Inhibition of CYP 3A4 by imatinib:
1 buprenorphine exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 buprenorphine exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib:
1 buprenorphine exposure 9, 18, 19 Other Acetaminophen --
Antimigraine preparations
Dihydroergotamine
1 dihydroergotamine exposure 9, 18, 19 • Inhibition of CYP 3A4 by dasatinib:
1 dihydroergotamine exposure 9, 18, 19 • Inhibition of CYP 3A4 by nilotinib: For personal use only. by guest on May 10, 2013. bloodjournal.hematologylibrary.org From been reported. 58, 59 Accordingly, nilotinib prescribing information includes a black box warning about the risk of QTc prolongation and sudden death and warns that nilotinib should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome, either congenital or drug induced. 58, 59 Conclusions Pharmacokinetics, drug interactions, and safety recommendations are best characterized for imatinib, which was the first TKI on the market. The other TKIs, just recently marketed, have so far only a limited documentation about clinically relevant interactions. Their concentration profile might be affected to a more dramatic degree by interactions than imatinib exposure.
The 3 TKIs reviewed are indeed substrates of several drug transporters and metabolizing enzymes. They are also capable of inhibiting drug transporters and enzymes, making their disposition and metabolism rather complex and difficult to predict.
Most of the available pharmacokinetic information is based on information obtained from in vitro experiments, animal studies, drug-drug interaction studies, and studies in healthy volunteers with a single dose of the aimed TKI. These results must be translated into treatment adjustment recommendations for the clinical oncology practice, where these drugs are administered on a daily basis in patients receiving various co-medications. The actual relevance of predicted drug interactions is thus still uncertain. Most of the interactions outlined in Table 1 (except those in boldface) are theoretical and have not been confirmed in clinical studies; therefore, they should only be considered indicative. Further interaction mechanisms may still be unknown at present.
We advise the reader to regularly monitor for updates about this topic. Therapeutic Drug Monitoring of TKIs 63 should be considered if a drug interaction is suspected, or in case of toxicity, or lack of satisfactory clinical response. Finally, documenting unexpected observations and reporting them to the Pharmacovigilance network is of definite importance. 17 The remaining authors declare no competing financial interests.
Correspondence 43, 44 • Induction of CYP 3A4 by St John's wort: 2 dasatinib exposure 56 • Induction of CYP 3A4 by St John's wort: 2 nilotinib exposure 9, 18 Grapefruit • Inhibition of CYP 3A4 and Pgp by grapefruit: 1 imatinib exposure 9, 18 • Inhibition of CYP 3A4 and Pgp by grapefruit: 1 dasatinib exposure 9, 18 • Inhibition of CYP 3A4 by grapefruit: 1 nilotinib exposure 62 
Licorice
• Inhibition of CYP 3A4 by licorice: 1 imatinib exposure 9, 18, 89 • Inhibition of CYP 3A4 by licorice: 1 dasatinib exposure 9, 18, 89 • Inhibition of CYP 3A4 
